DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE
Pre-Launchdolutegravir lamivudine tenofovir alafenamide
NDATABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing three antiretroviral agents: dolutegravir (integrase inhibitor), lamivudine (nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (nucleotide reverse transcriptase inhibitor). The combination is indicated for HIV-1 treatment, providing a complete regimen in a single tablet to improve patient adherence. It works by blocking viral integration, reverse transcription, and nucleotide incorporation simultaneously.
Pre-Launch
Pre-launch stage indicates significant opportunity for launch team expansion, including brand, market access, and field roles at Cipla's commercial organization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this pre-launch HIV combination positions you in a high-stakes, competitive therapeutic area with significant commercial upside if approval is achieved. Cipla's entry into the global HIV market signals investment in emerging and established markets, creating career mobility across geographies and functional areas.
Brand ManagerLaunch Manager
Worked on DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.